Compugen Ltd (CGEN)

Mar 26, 2025, 7:00 AM EDT - 4 weeks ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 4, 2025, 10:34 AM EST - 7 weeks ago

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 7:00 AM EST - 7 weeks ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 3, 2025, 7:00 AM EST - 7 weeks ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 2 months ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 18, 2025, 7:00 AM EST - 2 months ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 18, 2025, 6:11 AM EST - 2 months ago

Compugen: Immuno-Oncology Innovator Poised For A Comeback

Feb 4, 2025, 7:00 AM EST - 2 months ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 3 months ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Nov 27, 2024, 7:00 AM EST - 5 months ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 12, 2024, 3:35 PM EST - 5 months ago

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 5 months ago

Compugen Reports Third Quarter 2024 Results

Nov 11, 2024, 7:00 AM EST - 5 months ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 5, 2024, 9:00 AM EST - 6 months ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Oct 29, 2024, 7:00 AM EDT - 6 months ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 7, 2024, 7:00 AM EDT - 7 months ago

Compugen to Present New Clinical Data at SITC 2024

Sep 9, 2024, 7:00 AM EDT - 8 months ago

Compugen to Present at Single Cell Genomics 2024 Conference

Aug 29, 2024, 7:00 AM EDT - 8 months ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 10, 2024, 5:54 AM EDT - 9 months ago

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 9 months ago

Compugen Reports Second Quarter 2024 Results

Jul 29, 2024, 7:00 AM EDT - 9 months ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 23, 2024, 7:00 AM EDT - 9 months ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jun 17, 2024, 7:00 AM EDT - 11 months ago

Compugen to Present at Upcoming Antibody Industrial Symposium

May 30, 2024, 7:00 AM EDT - 11 months ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

May 20, 2024, 12:22 PM EDT - 1 year ago

Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript

May 20, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports First Quarter 2024 Results

May 16, 2024, 7:00 AM EDT - 1 year ago

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 15, 2024, 7:00 AM EDT - 1 year ago

Compugen Appoints David Silberman as Chief Financial Officer

May 6, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Compugen to Participate in Two Upcoming Investor Conferences

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Mar 6, 2024, 7:00 AM EST - 1 year ago

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Mar 5, 2024, 2:41 PM EST - 1 year ago

Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Fourth Quarter and Full Year 2023 Results

Feb 26, 2024, 7:00 AM EST - 1 year ago

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

Feb 20, 2024, 7:00 AM EST - 1 year ago

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

Feb 15, 2024, 7:00 AM EST - 1 year ago

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Jan 10, 2024, 8:01 AM EST - 1 year ago

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

AGEN BMY GSK ITOS MRK NVS PFE

Jan 8, 2024, 7:05 AM EST - 1 year ago

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

AZN

Jan 8, 2024, 7:00 AM EST - 1 year ago

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 19, 2023, 7:13 AM EST - 1 year ago

Compugen stock rockets on anti-tumor drug deal with Gilead

GILD

Dec 19, 2023, 7:10 AM EST - 1 year ago

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

AZN

Dec 19, 2023, 7:05 AM EST - 1 year ago

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

Dec 19, 2023, 7:00 AM EST - 1 year ago

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

GILD

Nov 7, 2023, 7:00 AM EST - 1 year ago

Compugen Reports Third Quarter 2023 Results

AZN

Nov 6, 2023, 7:00 AM EST - 1 year ago

Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy

Nov 3, 2023, 4:35 PM EDT - 1 year ago

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 31, 2023, 9:00 AM EDT - 1 year ago

Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer